🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Thank you to all our sites for having a fantastic month recruiting in January. At the end of last week Nottingham University Hospitals and R&D at UHCW recruited 2 participants . That's an amazing 13 participants recruited in Jan. We cant wait to see what February brings

MILESTONE ALERT: 400 women have now registered to participate in the trial. Thank you so much to our fantastic sites and wonderful participants for helping us to reach this amazing milestone. We are so close to answering this important question siobhan quenby Saskia Middeldorp Warwick CTU

Fantastic! So very happy with ALIFE 2 participants and investigators! INVENT-VTE

Many thanks to our wonderful sites UHCW, Manchester and Liverpool R&D at UHCW Maternal & Fetal Health Research Centre Liverpool Women's University Hospital for recruiting participants to the ALIFE 2 this week. Your amazing work has helped us to recruit 400 participants internationally. Thank you so much

A huge thank you to the team at Liverpool Women's Liverpool Women's University Hospital for recruiting your second participant to the ALIFE 2 this week. Keep up the fantastic work! That's 275 women registered to participate in the UK now. We are so close to finding an answer!

I know we can do this. Thank you to our ladies for taking part.

A huge thank you to our teams @NorthMidNHS and UCLH for recruiting participants to the ALIFE 2 this week. Keep up the fantastic work.

Fantastic! Also in the global sites we have recruitments! We all keep up the good work. #thrombophilia #miscarriage #lmwh INVENT-VTE ALIFE 2

Another curve: Progress of the ALIFE2 study: A dynamic road towards more evidence. Slowly, but we are getting there! #thrombophilia #miscarriage #LMWH ALIFE 2 INVENT-VTE siobhan quenby @ScheresLuuk Thrombosis Research thrombosisresearch.com/article/S0049-…

Happy news: we have seen a boost in randomizations in the ALIFE 2. Women with recurrent #miscarriage and #thrombophilia are allocated to #LMWH or standard of care. Lots of new #pregnancies and hope after lockdown 🥰 alife2study.org INVENT-VTE

Saskia Middeldorp ALIFE 2 INVENT-VTE I’ve been waiting for the results!! :)

Saskia Middeldorp ALIFE 2 INVENT-VTE Great trial. Critcal data.

MILESTONE ALERT: This week we reached a huge milestone. Over 300 women have now been randomised. We are so so close to finishing this important trial! Its the final countdown ... Warwick CTU siobhan quenby Saskia Middeldorp

📣Publication alert: finally published in The Lancet , the ALIFE2 trial. So thankful to all women who participated and all colleagues who joined the study. LMWH does NOT improve live birth in women with #thrombophilia and #recurrent miscarriage. thelancet.com/pb-assets/Lanc…

Today the ALIFE2 Trial was published in The Lancet - thank you to all the women who participated and colleagues who supported the trial authors.elsevier.com/c/1hAohV-4XL1xJ

New study: Many women with recurrent miscarriage are tested for inherited thrombophilia. If confirmed positive, daily subcutaneous low-molecular-weight heparin (LMWH) is given. This is despite an absence of evidence that such treatment is beneficial 🧵 hubs.li/Q01S2WvV0

An international, open-label RCT "showed no significant difference in livebirth rates in women with recurrent pregnancy loss and confirmed inherited thrombophilia after treatment with LMWH treatment when compared with standard care alone", write authors. Research in context ⤵️

Based on trial findings, authors do not advise the use of LMWH in this population or screening for inherited thrombophilia in women with recurrent pregnancy loss.

Alongside decreasing the treatment burden and associated costs, "the results also mean that researchers can focus research on other solutions for recurrent pregnancy loss after decades of investigating anticoagulants", say siobhan quenby and colleagues.

Always great to get an answer even if it’s negative treatment outcome. University Hospitals Birmingham recruited a record number of patients into the trial - big thanks to all the patients who participated, you have made an impact on thousands of women 👏 siobhan quenby